Egis Gyogyszergyar Nyilvanosan Mukodo Reszvenytarsasag

Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag

Eva Sipos

Balazs Volk

Jozsef Barkoczy

Gyorgyi Kovanyine Lax

Gyula Simig

Kalman Nagy

Ferenc Lorant Bartha

Gyula Lukacs

Gyorgy Krasznai

Gyorgy Ruzsics

Balazs Havasi

Adrienn Keszthelyi

Maria Tothne Lauritz

Janos Imre

Ferenc Jurak

Gyoergy Ruzsics

Imre Markovits

Gyoergyi Kovanyine Lax

Andras Boza

Imre Kiraly

Gabor Bagyinszki

Adrienn Karasz

Gyorgy Morovjan

Monika Mezovari

Katalin Kataine Fadgyas

Zsolt Runge

Csaba Hamori

Maria Julia Taborine Toth

Laszlo Jozsef Hegedus

The invention relates to a process for the preparation of 5-chloro-N-({(5-S)-2-oxo3-[4-(3-oxo-morj)holine-4-yl)-phenyl]-1,3-oxazolidine-5-yl}-methyl) thiophen-2-carboxamide having the INN rivaroxaban. The invention also relates to intermediates formed in the above process.

Process for the preparation of a rivaroxaban and intermediates formed in said process

The present invention is related to crystalline forms of rosuvastatin zinc (2:1) salt. The polymorphs are suitable for use as pharmaceutically active ingredients in the treatment of the diseases of the lipid metabolism including hypercholesterolemia, hyperlipidemia, dyslipidemia or atherosclerosis. 

Crystalline pharmaceutically active ingredients

The present invention is related to intermediates useful in the preparation of pharmaceutically acceptable salts of (+)-7-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-pyrimidin-5-yl]-(3R,5S)-dihydroxy-hept-6-enoic acid and polymorphs of said intermediates, methods for preparation thereof and use thereof.

Method for the preparation of high-purity pharmaceutical intermediates

The present invention relates to a new process for the preparation of rosuvastatin [7-[4-(4-Fluorophenyl)-6-isopropyl-2-(methanesulphonyl-methyl-amino)-pyrimidin-5-yl]-(3R,51S)-dihydroxy-hept-6-enoic acid] of the formula (I) salts formed with bivalent cations, preferably with calcium or zinc ions, characterized in that rosuvastatin tert.-butylammonium salt is reacted with the appropriate bivalent cation, preferably with calcium or zinc ions in a mixture of a water immiscible or slightly miscible organic solvent and water and the formed salt is isolated. 

Process for the preparation of rosuvastatin salts

Growing community of inventors

Budapest, Hungary

Eva Sipos